WestPark Capital initiated coverage of Enanta (ENTA) with a Buy rating and $24 price target
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
- Enanta Pharmaceuticals Appoints Interim Financial Officers
- Enanta Pharmaceuticals Sues Pfizer Over Patent Infringement
- Enanta files EU patent infringement suit against Pfizer
- Enanta Pharmaceuticals: Hold Rating Amid Strategic Advances and Financial Constraints
- Enanta Pharmaceuticals: Promising Outlook with Key Data Readouts and Strong Virology Pipeline